PURPOSE: I-labeled human serum amyloid P component (SAP) is used clinically only in the UK for imaging visceral amyloidosis to assist with diagnosis, disease staging, and monitoring response to therapy. We compare a new amyloid-reactive probe, peptide p5, with SAP for imaging amyloidosis. PROCEDURES: Dual-energy SPECT/CT images were acquired of (125)I-labeled SAP and (99m)Tc-labeled p5 in mice with systemic AA amyloidosis (n = 3). Twelve organs and tissues were harvested for radiotracer biodistribution assessment and for micro-autoradiographic analysis. RESULTS: I-SAP and (99m)Tc-p5 localized equivalently in amyloid deposits in liver (∼10% injected dose (ID)/g) whereas (125)I-SAP was twofold higher in the spleen (∼20% ID/g; (99m)Tc-p5, ∼10% ID/g). In contrast, (99m)Tc-p5 was bound to pancreatic and intestinal amyloid approximately fivefold more efficiently as evidenced in biodistribution data. CONCLUSIONS: Radiolabeled p5 is an effective amyloid-imaging radiotracer as compared to SAP in the murine model of amyloidosis and may be rapidly translated for imaging patients with visceral amyloidosis in the USA.
PURPOSE: I-labeled humanserum amyloid P component (SAP) is used clinically only in the UK for imaging visceral amyloidosis to assist with diagnosis, disease staging, and monitoring response to therapy. We compare a new amyloid-reactive probe, peptide p5, with SAP for imaging amyloidosis. PROCEDURES: Dual-energy SPECT/CT images were acquired of (125)I-labeled SAP and (99m)Tc-labeled p5 in mice with systemic AA amyloidosis (n = 3). Twelve organs and tissues were harvested for radiotracer biodistribution assessment and for micro-autoradiographic analysis. RESULTS: I-SAP and (99m)Tc-p5 localized equivalently in amyloid deposits in liver (∼10% injected dose (ID)/g) whereas (125)I-SAP was twofold higher in the spleen (∼20% ID/g; (99m)Tc-p5, ∼10% ID/g). In contrast, (99m)Tc-p5 was bound to pancreatic and intestinal amyloid approximately fivefold more efficiently as evidenced in biodistribution data. CONCLUSIONS: Radiolabeled p5 is an effective amyloid-imaging radiotracer as compared to SAP in the murine model of amyloidosis and may be rapidly translated for imaging patients with visceral amyloidosis in the USA.
Authors: Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Sallie Macy; Emily B Martin; Angela Williams; Keiichi Higuchi; Stephen J Kennel Journal: Proc Natl Acad Sci U S A Date: 2011-08-01 Impact factor: 11.205
Authors: A Solomon; D T Weiss; M Schell; R Hrncic; C L Murphy; J Wall; M D McGavin; H J Pan; G W Kabalka; M J Paulus Journal: Am J Pathol Date: 1999-04 Impact factor: 4.307
Authors: Jonathan S Wall; Stephen J Kennel; Michael J Paulus; Shaun Gleason; Jens Gregor; Justin Baba; Maria Schell; Tina Richey; Brian O'Nuallain; Robert Donnell; Philip N Hawkins; Deborah T Weiss; Alan Solomon Journal: Amyloid Date: 2005-09 Impact factor: 7.141
Authors: Bouke P C Hazenberg; Martin H van Rijswijk; D Albertus Piers; Marjolijn N Lub-de Hooge; Edo Vellenga; Elizabeth B Haagsma; Philip N Hawkins; Pieter L Jager Journal: Am J Med Date: 2006-04 Impact factor: 4.965
Authors: Jonathan S Wall; Angela Williams; Tina Richey; Alan Stuckey; Craig Wooliver; J Christopher Scott; Robert Donnell; Emily B Martin; Stephen J Kennel Journal: Mol Imaging Biol Date: 2017-10 Impact factor: 3.488
Authors: Jonathan S Wall; Tina Richey; Sally Macy; Eric Heidel; Craig Wooliver; Stephen J Kennel Journal: Amyloid Date: 2013-01-17 Impact factor: 7.141
Authors: Emily B Martin; Angela Williams; Eric Heidel; Sallie Macy; Stephen J Kennel; Jonathan S Wall Journal: Biochem Biophys Res Commun Date: 2013-05-23 Impact factor: 3.575
Authors: Emily B Martin; Stephen J Kennel; Tina Richey; Craig Wooliver; Dustin Osborne; Angela Williams; Alan Stuckey; Jonathan S Wall Journal: Peptides Date: 2014-08-04 Impact factor: 3.750
Authors: Stephen J Kennel; Angela Williams; Alan Stuckey; Tina Richey; Craig Wooliver; Walter Chazin; David A Stern; Emily B Martin; Jonathan S Wall Journal: Amyloid Date: 2015-12-24 Impact factor: 7.141